se gb

CCS Healthcare and Lipidor cooperate on new skin care technology for use in new products

CCS Healthcare, one of the Nordic region’s largest manufacturers of skin care products, pharmaceuticals and hygiene products, licenses the new AKVANO® technology, developed by Lipidor AB.

CCS Healthcare has a turnover of about 500 MSEK divided into hygiene and skin care products, pharmaceuticals, dental, and contract manufacturing.

“Having access to AKVANO technology will enable us to develop CCS-products in a new way for hygiene and skin care products and pharmaceuticals. We will be able to offer our customers new competitive solutions within our core product areas”, says Jonas Nilsson, CEO of CCS Healthcare. The licensing of AKVANO is in line with the company´s strategy to expand its offering of new and interesting products in its core market segments, hygiene and skin care.

“We are very excited about this product cooperation with CCS Healthcare. We see great opportunities for successful product launches in a number of different markets”, says Anders Carlsson, CEO of Lipidor AB.
AKVANO technology represents a completely new dosage form that creates a lipid layer on the skin sur-
face for effective topical delivery of drugs and skin care treatment. AKVANO’s innovative and easily applied formulations offer significant advantages over many currently available ointments and creams.

For additional information, contact:
Jonas Nilsson, CEO, CCS Healthcare AB,
Anders Carlsson, CEO, Lipidor AB,

CCS Healthcare AB is one of the Nordic region’s largest manufacturers of skin care products, pharmaceuticals and hygiene products. Products from CCS are distributed mainly through pharmacies, county councils and retail chains all over the Nordic region and in several other European markets. CCS Healthcare manufactures and markets well-known brands such as Hydrokortison CCS, Olivia by CCS, DAX, CCS Swedish Formula, and Antibac.

Lipidor AB is a Swedish drug delivery company established in 2009. The Company is focused on the de-
velopment and commercialization of its AKVANO® technology, a new proprietary class of topical medication. AKVANO offers “lipid layer” product opportunities across dermatology, wound & burn care and skin care markets. Research and development is conducted at Karolinska Institutet and Stockholm University.